The clinical value and sensitivity of serum caffeine clearance measurement has been evaluated as an indicator of hepatic disease. After a 17 hour caffeine exclusion period, 300 mg of caffeine citrate was administered orally to the study subjects. With the development of hepatic transplantation, the need for a simple informative liver function test that provides possible prognostic information, such as creatinine
min/kg, range 0.23-2-64 mllmin/kg) and significantly different, p<0 001, from those of subjects with liver disease. Serum albumen values were not different for these latter two groups. Using a cut offvalue of0-86 mllmin/kg, caffeine clearance measurement was 100% sensitive for alcoholic liver disease and 89% sensitive for all liver disease. The Group IV comprised 21 patients with suspected liver disease. Their mean age was 61-8 years (range 20-85 years). This group included patients who were initially suspected of having liver disease because of abnormal liver function tests or hepatomegaly but who were subsequently shown to have an alternative explanation for these abnormalities, see Table I . Group V comprised six patients with hepatic tumours. Their mean age was 72 years (range 38-90 years). There was one hepatoma in a subject with haemochromatosis, one cholangiocarcinoma, and four subjects with advanced metastatic adenocarcinomata.
Group VI comprised 21 hospital control subjects. Their mean age was 56.9 years (range 23-82 years). This group consisted of inpatients on the medical unit who were known not to have liver disease (suspected or proved), see Table II .
Group VII comprised 14 normal control subjects. Their mean age was 33.5 years (range 24-48 years). This group consisted of healthy hospital staff.
Informed consent was obtained from all subjects and the study received approval from the district ethical committee in May 1989.
EXPERIMENTAL PROCEDURE
The subjects complied with a caffeine free diet from midnight before the test. At 5 pm on the day of the test, 300 mg of caffeine citrate was administered orally to each subject in two cups of decaffeinated coffee. Venous blood was taken at 9 pm and at 9 am the following morning when the caffeine restriction was lifted. Blood for conventional liver function tests was taken with the morning sample.
ANALYTICAL METHODS
Routine liver function tests were undertaken using standard methods in the hospital laboratory. Serum samples were stored at -20°C and 
in batches. Caffeine serum concentrations were determined by the method described by Zysset et al,4 using an automated enzyme immunoassay kit supplied by Syva, UK. Caffeine content remained stable for at least three months under these storage conditions. In five subjects (three controls and two with stable liver disease) reproducibility was assessed by repeating the test after a month. The coefficient of variation was 13-7%.
The caffeine elimination constant (kel) was calculated assuming first order kinetics. A recent study5 has confirmed the validity of estimating caffeine clearance using only two data points. Previous studies in man have shown that caffeine elimination follows first order kinetics after this oral dose, which is maintained beyond several half lives.6 Caffeine clearance was calculated as Cl=kelXVd, using a constant volume of distribution of 0-61/kg body weight. Other studies have shown that caffeine distributes in total body water and that Vd for caffeine is not significantly different in cirrhotic patients.
STATISTICS
All comparisons between groups have been made using the Mann-Whitney U test. Sensitivity is defined as the number of true positives in a population as a proportion of true positives plus false negatives; specificity is defined as the number of true negatives in a population as a proportion of true negatives plus false positives.
Results
The individual results for measurement of caffeine clearance are shown in Figure 1 and the median values for each group are shown in Table  III with serum albumen results for comparison. Caffeine clearance is most depressed in the patients with alcoholic liver disease and significantly different (p=0.003) even when compared with non-alcoholic cirrhosis. There is no significant difference in the albumen measurement for these two groups. In the suspected liver disease group, caffeine clearance values were not different from normal values but were significantly higher than values for subjects with proved liver disease (p<0-001) despite noticeable abnormalities in liver enzyme and bilirubin measurements. This is best shown for the subjects with jaundice associated with obstructing common duct stones whose caffeine clearance values were all normal (see Table I ). Their respective peak bilirubin values were 163, 251, 39, 20, and 53 [tmol/l. Subjects with hepatic tumours tended to have noticeably depressed caffeine clearance values (see Fig 1) but all had advanced disease requiring admission for terminal care planning. The one subject with a normal value had a metastatic adenocarcinoma affecting the liver.
A value of 0-86 ml/min/kg has been used as a cut off value (mean of normal control values minus 1 SD),' for assessing sensitivity and specificity. In the alcoholic liver disease group caffeine clearance measurement was 100% sensitive compared with a 76% sensitivity for conventional liver function tests. Conventional liver In the suspected liver disease group, the caffeine clearance measurement was abnormal in only 24% of subjects compared with abnormal liver function tests in 95%, the latter reflecting the underlying disease rather than structural liver disease. Specificity for liver function tests and caffeine clearance measurement was 100% and 93% respectively in normal control subjects. In the hospital control group the specificity of caffeine clearance measurement was poor (62%).
Discussion
Since the initial observation that the half life of caffeine is prolonged in patients with alcoholic liver disease,7 several studies have shown that caffeine clearance measurement is a reliable indicator of the severity of liver disease.' 458 After the introduction of an EMIT kit for the assay of caffeine, the measurement of caffeine in biological fluids is now an inexpensive and simple procedure that any laboratory can establish. The potential value of this measurement has been assessed in a district hospital setting.
An arbitrary lower limit of normal for caffeine clearance measurement has been set at 0.86 ml/ min/kg. This has been derived from a rather small control population but is similar to the value of 1.07 ml/min/kg derived by Jost et al' (and shown for comparison in the Figure) . A more useful cut off value might be derived by receiver operating curve (ROC) analysis. Nevertheless, the derived values for specificity and sensitivity give some impression of test performance. Caffeine clearance measurement alone is at least as useful as conventional liver function tests in detecting liver disease but we feel that its measurement, in addition to conventional liver function test measurement, gives a more comprehensive indication of the severity of the liver disease. This is certainly indicated in our data relating to cirrhosis, where 91% of those with this disorder have an abnormal caffeine clearance value, whose median of 0-38 ml/min/ kg is significantly lower than that ofpatients with non-cirrhotic liver disease (078 ml/min/kg p=004). A number of transplant centres use caffeine clearance measurement as a useful prognostic indicator and there is evidence that it is a more sensitive indicator of declining hepatic function than the aminopyrine breath test.9 After orthotopic liver transplantation, caffeine clearance measurement is a poor means of predicting impending transplant rejection.'0 This is not surprising in a structurally normal organ where the predominant injury, except in severe cases, is periportal. Changes probably occur too rapidly in this situation for any function test to perform more reliably than simple enzyme estimation and histology. A recent study has shown that the inclusion of a test of hepatic metabolic function in the assessment of the prognosis of liver disease greatly simplifies the process, reducing the number of variables required."
Caffeine clearance values were low in a number of hospital control subjects. This may have reflected the severity of their underlying disease or incomplete information concerning possible liver disease. Potential drug interference with the assay and inhibition of caffeine metabolism were avoided as far as possible, although changing complex drug therapy may have had an influence. Many studies have shown the wide variation in caffeine clearance values between individuals, often influenced by environmental factors such as smoking. This contributes to the difficulty in establishing a clear threshold value for 'normal'. Information on smoking habits was obtained from all subjects but separate analysis by smoking habit did not improve discrimination between or within the various groups. In fact only 27 subjects were current smokers. The highest observed clearance value (3-1 in a normal control) was in the heaviest smoker! In the patients with cirrhosis not related to alcohol, three had normal caffeine clearance values; one with chronic active hepatitis, one with sclerosimg cholangitis, and one with haemachromatosis. The last subject was the only smoker. Ofthe subjects with normal caffeine clearance values who had liver disease (n=6), only two were current smokers while four of the 20 subjects with low values were also smokers. Twelve of the 21 patients with alcoholic liver disease were current smokers but their caffeine clearance values (median 0-23 ml/min/kg) were lower than those of non-smokers in the same group (median 0-37 ml/min/kg). Thus, in this study smoking habit did not have any consistent influence on the interpretation of the results.
In the present study it is striking that those with alcoholic liver disease have 
